Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus atezolizumab vs placebo plus atezolizumab after resection and adjuvant chemotherapy in PD-L1 positive stage II–III NSCLC
2023-506696-10-00Phase 3Completed
- Sponsor
- Roche
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tiragolumab plus atezolizumab with Placebo plus atezolizumab (2 arms). Primary endpoint: Incidence and severity of adverse events. Started May 2024; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506696-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506696-10-00.